Neurocrine Biosciences
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | in 1992 by Larry Bock, Wylie Vale, Larry Steinman, Kevin Gorman |
| Headquarters | San Diego, California, U.S. |
Key people | William Rastetter (chairman) Kyle Gano (CEO) |
| Revenue | US$788 million (2019) |
Number of employees | 1,350 (June 30, 2023) |
| Website | neurocrine |
| Footnotes / references | |
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.